Physician profile
Tabitha Indries
NPI 1639602766
$2,022.48
in general payments reported to CMS, 2019-2025
17 companies · $11.31 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,076 · 2022: $879 · 2023: $18.19 · 2024: $38.25 · 2025: $11.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $67.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $67.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $640.73 | 2021-2022 | |
| Evofem Biosciences, INC. | $620.54 | 2021-2025 | Phexxi, Solosec, Phexx |
| Pfizer INC. | $156.83 | 2021-2023 | |
| Coopersurgical, INC. | $113.87 | 2021-2022 | |
| Organon LLC | $73.74 | 2021-2022 | |
| Hologic Sales and Service, LLC | $66.48 | 2021-2024 | Acessa Provu System |
| Agile Therapeutics, INC. | $58.04 | 2021 | |
| Mayne Pharma Commercial LLC | $48.67 | 2022 | |
| Therapeuticsmd, INC. | $44.53 | 2021 | |
| Aspira Women'S Health INC | $35.23 | 2022 | |
| Mylan Pharmaceuticals INC. | $29.14 | 2021 | |
| Roche Diagnostics Corporation | $26.56 | 2021 | |
| Exeltis, USA INC. | $24.36 | 2022 | |
| Myovant Sciences INC. | $23.75 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.34 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $20.30 | 2021 | |
| Daiichi Sankyo INC. | $18.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabitha Indries listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.